Eikon Therapeutics logo

Eikon Therapeutics, Inc.


Eikon Therapeutics Stock

Eikon Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of severe neurological disorders. The company's lead product candidate, EKT-101, is an investigational gene therapy for the treatment of Angelman syndrome (AS), a rare genetic disorder characterized by severe intellectual disability and seizures.

Management Team

Roger Perlmutter CEO
Alfred Bowie CFO
Russ Berman CTO
Ashish Kheterpal Chief Information Officer
Dan Anderson Chief Scientific Officer
Benjamin Thorner Chief Business Officer
Barbara Howes Chief People Officer
Roy Baynes Chief Medical Officer

Notable Investors

Funding Information